A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT04231747 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma Non-Hodgkin
Agressive Lymphoma
Diffuse-large B-cell Lymphoma (DLBCL)

Interventions

BIOLOGICAL: CC-97540

Sponsor

Juno Therapeutics, a Subsidiary of Celgene